Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
The role of low-density lipoproteins (LDLs) as a major risk factor for cardiovascular disease has been demonstrated by several epidemiological studies. The molecular basis for LDLs in atherosclerotic plaque formation and progression is not completely unraveled yet. Pharmacological modulation of plas...
Main Authors: | Giovanni Ciccarelli, Saverio D’Elia, Michele De Paulis, Paolo Golino, Giovanni Cimmino |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-03-01
|
Series: | Diseases |
Subjects: | |
Online Access: | http://www.mdpi.com/2079-9721/6/1/22 |
Similar Items
-
Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01) -
PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01) -
Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-12-01) -
LDL Cholesterol, Statins And PCSK 9 Inhibitors
by: Sanjiv Gupta
Published: (2015-09-01) -
High-density lipoproteincholesterol, reverse cholesterol transport, and cardiovascular risk: a tale of genetics?
by: Giovanni Cimmino, et al.
Published: (2013-10-01)